Table 1 Comparison of baseline clinical characteristics of RA subjects at the time of their 1st b/tsDMARD across medication sequence clusters
Cluster 1: TNFi persister | Cluster 2: TNFi/abatacept | Cluster 3: Rituximab/multiple bDMARD | Cluster 4: Multiple bDMARD/tocilizumab | P-value | |
|---|---|---|---|---|---|
Age at 1st biologic, mean (SD) | 51 (16) | 54 (15) | 57 (15) | 55 (14) | < 0.001 |
Female | 74% | 87% | 83% | 77% | < 0.001 |
Race | 0.104 | ||||
White | 84% | 77% | 83% | 84% | |
Black | 5.8% | 11% | 9% | 7.3% | |
Other | 11% | 13% | 8.5% | 9.1% | |
Hispanic | 4.4% | 8.0% | 3.6% | 4.4% | 0.143 |
RA follow-upa, median years [IQR] | 1.5 [0.65, 4.5] | 1.8 [0.88, 3.5] | 2.9 [0.81, 6.2] | 1.5 [0.57, 4.8] | < 0.001 |
Follow-up timeb, median years [IQR] | 5.2 [3.0, 7.3] | 5.8 [3.9, 7.7] | 4.2 [2.4, 6.6] | 4.7 [2.8, 7.3] | < 0.001 |
Seropositivity | 57% | 72% | 73% | 69% | < 0.001 |